Supplementary file belonging to

# From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling

Véronique M.P. de Bruijn1 & Ivonne M.C.M. Rietjens1

1 Division of Toxicology, Wageningen University and Research, Wageningen, The Netherlands

## Bibliography for *in vivo* data

Addison, R. S., Franklin, M. E. and Hooper, W. D. (1998). Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. *J Chromatogr B Biomed Sci Appl 716*, 153-160. doi:10.1016/s0378-4347(98)00285-0

Anderson, K., Nelson, C. H., Gong, Q. et al. (2022). Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants. *Clin Pharmacol Drug Dev 11*, 235-245. doi:10.1002/cpdd.1015

Ankier, S. I., Martin, B. K., Rogers, M. S. et al. (1981). Trazodone--a new assay procedure and some pharmacokinetic parameters. *Br J Clin Pharmacol 11*, 505-509. doi:10.1111/j.1365-2125.1981.tb01157.x

Azie, N. E., Brater, D. C., Becker, P. A. et al. (1998). The interaction of diltiazem with lovastatin and pravastatin. *Clin Pharmacol Ther 64*, 369-377. doi:10.1016/S0009-9236(98)90067-4

Baxter, J. G., Brass, C., Schentag, J. J. et al. (1986). Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. *J Pharm Sci 75*, 443-447. doi:10.1002/jps.2600750504

Blum, R. A., D'Andrea, D. T., Florentino, B. M. et al. (1991). Increased gastric ph and the bioavailability of fluconazole and ketoconazole. *Ann Intern Med 114*, 755-757. doi:10.7326/0003-4819-114-9-755

Braeckman, R. A., Stirtan, W. G. and Soni, P. N. (2015). Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects. *Clin Pharmacol Drug Dev 4*, 143-148. doi:10.1002/cpdd.150

Bramer, S. L., Brisson, J., Corey, A. E. et al. (1999). Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. *Clin Pharmacokinet 37 Suppl 2*, 69-77. doi:10.2165/00003088-199937002-00008

Bucher, M., Mair, G. and Kees, F. (2002). Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. *Eur J Clin Pharmacol 57*, 787-791. doi:10.1007/s00228-001-0385-6

Caro, L., Prueksaritanont, T., Fandozzi, C. M. et al. (2021). Evaluation of pharmacokinetic drug interactions of the direct-acting antiviral agents elbasvir and grazoprevir with pitavastatin, rosuvastatin, pravastatin, and atorvastatin in healthy adults. *Clin Drug Investig 41*, 133-147. doi:10.1007/s40261-020-00974-8

Carver, P. L., Berardi, R. R., Knapp, M. J. et al. (1994). In vivo interaction of ketoconazole and sucralfate in healthy volunteers. *Antimicrob Agents Chemother 38*, 326-329. doi:10.1128/AAC.38.2.326

Chapelsky, M. C., Thompson-Culkin, K., Miller, A. K. et al. (2003). Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. *J Clin Pharmacol 43*, 252-259. doi:10.1177/0091270002250602

Chen, C. H., Yang, J. C., Uang, Y. S. et al. (2013). Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. *Int J Pharm 444*, 18-24. doi:10.1016/j.ijpharm.2013.01.028

Chen, J., Xu, Y., Lou, H. et al. (2020). Effect of genetic polymorphisms on the pharmacokinetics of deferasirox in healthy chinese subjects and an artificial neural networks model for pharmacokinetic prediction. *Eur J Drug Metab Pharmacokinet 45*, 761-770. doi:10.1007/s13318-020-00647-z

Chin, T. W., Loeb, M. and Fong, I. W. (1995). Effects of an acidic beverage (coca-cola) on absorption of ketoconazole. *Antimicrob Agents Chemother 39*, 1671-1675. doi:10.1128/AAC.39.8.1671

Chirnomas, D., Smith, A. L., Braunstein, J. et al. (2009). Deferasirox pharmacokinetics in patients with adequate versus inadequate response. *Blood 114*, 4009-4013. doi:10.1182/blood-2009-05-222729

Chu, K. M., Hu, O. Y., Pao, L. H. et al. (2007). Pharmacokinetics of oral rosiglitazone in taiwanese and post hoc comparisons with caucasian, japanese, korean, and mainland chinese subjects. *J Pharm Pharm Sci 10*, 411-419. doi:10.18433/j3159d

Cox, P. J., Ryan, D. A., Hollis, F. J. et al. (2000). Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. *Drug Metab Dispos 28*, 772-780.

D'Souza, D. L., Dimmitt, D. C., Robbins, D. K. et al. (2001). Effect of alosetron on the pharmacokinetics of fluoxetine. *J Clin Pharmacol 41*, 455-458. doi:10.1177/00912700122010177

Danafar, H. and Hamidi, M. (2015). Pharmacokinetics and bioequivalence study of amlodipine and atorvastatin in healthy male volunteers by lc-ms. *Pharmaceutical Sciences 21*, 167-174. doi:10.15171/ps.2015.32

Daneshmend, T. K., Warnock, D. W., Ene, M. D. et al. (1984). Influence of food on the pharmacokinetics of ketoconazole. *Antimicrob Agents Chemother 25*, 1-3. doi:10.1128/AAC.25.1.1

Danielak, D., Milanowski, B., Wentowski, K. et al. (2020). Physiologically based dissolution testing in a drug development process-a case study of a successful application in a bioequivalence study of trazodone er formulations under fed conditions. *AAPS PharmSciTech 21*, 161. doi:10.1208/s12249-020-01662-8

Dieterle, W., Corynen, S., Vaidyanathan, S. et al. (2005). Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. *Int J Clin Pharmacol Ther 43*, 527-535. doi:10.5414/cpp43527

Donovan, J. M., Kisicki, J. C., Stiles, M. R. et al. (2002). Effect of colesevelam on lovastatin pharmacokinetics. *Ann Pharmacother 36*, 392-397. doi:10.1345/aph.1A144

Doser, K., Guserle, R., Kramer, R. et al. (1997). Bioequivalence evaluation of two flutamide preparations in healthy female subjects. *Arzneimittelforschung 47*, 213-217.

Edema, O., Adeagbo, B. A., Adehin, A. et al. (2018). Bidirectional pharmacokinetic interaction between amodiaquine and pioglitazone in healthy subjects. *The Journal of Clinical Pharmacology 58*, 1061-1066.

Elmekawy, H. A., Belal, F., Abdelaziz, A. E. et al. (2021). Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male egyptian volunteers. *Eur J Clin Pharmacol 77*, 1369-1379. doi:10.1007/s00228-021-03130-z

Farkas, D., Volak, L. P., Harmatz, J. S. et al. (2009). Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. *Clin Pharmacol Ther 85*, 644-650. doi:10.1038/clpt.2008.293

Floriddia, M. L., Castorina, M. and Drago, F. (2000). Comparative bioavailability of a new formulation of fluoxetine drops. *Eur Rev Med Pharmacol Sci 4*, 9-13.

Freed, M. I., Allen, A., Jorkasky, D. K. et al. (1999). Systemic exposure to rosiglitazone is unaltered by food. *Eur J Clin Pharmacol 55*, 53-56. doi:10.1007/s002280050592

Frohlich, M., Burhenne, J., Martin-Facklam, M. et al. (2004). Oral contraception does not alter single dose saquinavir pharmacokinetics in women. *Br J Clin Pharmacol 57*, 244-252. doi:10.1111/j.1365-2125.2003.01983.x

Fukazawa, I., Uchida, N., Uchida, E. et al. (2004). Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in japanese. *Br J Clin Pharmacol 57*, 448-455. doi:10.1046/j.1365-2125.2003.02030.x

Gammans, R. E., Mackenthun, A. V. and Russell, J. W. (1984). Comparative bioavailability of trazodone formulations using stable isotope methodology. *Br J Clin Pharmacol 18*, 431-437. doi:10.1111/j.1365-2125.1984.tb02485.x

Gandelman, K., Malhotra, B., R. LaBadie, R. et al. (2011). Analytes of interest and choice of dose: Two important considerations in the design of bioequivalence studies with atorvastatin. *Journal of Bioequivalence & Bioavailability 03*, 62-68. doi:10.4172/jbb.1000060

Groenendaal-van de Meent, D., den Adel, M., Kerbusch, V. et al. (2022). Effect of roxadustat on the pharmacokinetics of simvastatin, rosuvastatin, and atorvastatin in healthy subjects: Results from 3 phase 1, open-label, 1-sequence, crossover studies. *Clin Pharmacol Drug Dev 11*, 486-501. doi:10.1002/cpdd.1076

Guan, X., Yin, L., Yang, Y. et al. (2018). Quantitation of lovastatin and its hydroxy acid in human plasma by high-performance liquid chromatography-tandem mass spectrometry. *Journal of Liquid Chromatography & Related Technologies 41*, 668-675. doi:10.1080/10826076.2018.1508473

Guo, C. X., Pei, Q., Yin, J. Y. et al. (2012). Effects of ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. *Xenobiotica 42*, 784-790. doi:10.3109/00498254.2012.661100

He, L., Wickremasingha, P., Lee, J. et al. (2014). Lack of effect of colesevelam hcl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. *Diabetes Res Clin Pract 104*, 401-409. doi:10.1016/j.diabres.2013.12.033

Hsu, H. C. and Chen, S. J. (1997). Pharmacokinetic behavior of ketoconazole in adult chinese males. *Journal of Food and Drug Analysis 5*, 193-198.

Huang, F., Marzin, K., Koenen, R. et al. (2017). Effect of steady-state faldaprevir on pharmacokinetics of atorvastatin or rosuvastatin in healthy volunteers: A prospective open-label, fixed-sequence crossover study. *J Clin Pharmacol 57*, 1305-1314. doi:10.1002/jcph.931

Huang, Y. C., Colaizzi, J. L., Bierman, R. H. et al. (1986). Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. *Antimicrob Agents Chemother 30*, 206-210. doi:10.1128/AAC.30.2.206

Jaakkola, T., Backman, J. T., Neuvonen, M. et al. (2005). Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. *Clinical Pharmacology & Therapeutics 77*, 404-414.

Jovanovic, D., Kilibarda, V., Dordevic, S. et al. (2006). Bioequivalence testing of a new tablet formulation of generic fluoxetine. *Eur J Drug Metab Pharmacokinet 31*, 35-40. doi:10.1007/BF03190640

Kale, P. and Agrawal, Y. K. (2015). Pharmacokinetics of single oral dose trazodone: A randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. *Front Pharmacol 6*, 224. doi:10.3389/fphar.2015.00224

Kantola, T., Kivisto, K. T. and Neuvonen, P. J. (1998). Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. *Clin Pharmacol Ther 63*, 397-402. doi:10.1016/S0009-9236(98)90034-0

Kasichayanula, S., Liu, X., Shyu, W. et al. (2011). Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. *Diabetes, Obesity and Metabolism 13*, 47-54.

KATCHEN, B. and BUXBAUM, S. (1975). Disposition of a new, nonsteroid, antiandrogen, α, α, α-trifluoro-2-methyl-4′-nitro-m-propionotoluidide (flutamide), in men following a single oral 200 mg dose. *The Journal of Clinical Endocrinology & Metabolism 41*, 373-379.

Khaliq, Y., Gallicano, K., Tisdale, C. et al. (2001). Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. *Br J Clin Pharmacol 51*, 591-600. doi:10.1046/j.1365-2125.2001.01393.x

Khan, I. M., Khan, B. T., Najmi, M. H. et al. (2016). Bioequivalence study of atorvastatin by hplc with uv-detection. *Rawal Medical Journal 41*, 354-359.

Kim, K. A., Park, P. W., Kim, H. K. et al. (2005). Effect of quercetin on the pharmacokinetics of rosiglitazone, a cyp2c8 substrate, in healthy subjects. *J Clin Pharmacol 45*, 941-946. doi:10.1177/0091270005278407

Kim, S., Seo, J. D., Yun, Y. M. et al. (2022). Pharmacokinetics and genetic factors of atorvastatin in healthy korean subjects. *Front Genet 13*, 836970. doi:10.3389/fgene.2022.836970

Kivisto, K. T., Kantola, T. and Neuvonen, P. J. (1998). Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. *Br J Clin Pharmacol 46*, 49-53. doi:10.1046/j.1365-2125.1998.00034.x

Kondratenko, S. N., Savelyeva, M. I., Kukes, V. G. et al. (2019). Experimental and clinical pharmacokinetics of fluoxetine and amitriptyline: Comparative analysis and possible methods of extrapolation. *Bull Exp Biol Med 167*, 356-362. doi:10.1007/s10517-019-04526-9

Kosoglou, T., Kumar, B., Statkevich, P. et al. (2015). Vorapaxar, an oral par-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone. *Clin Pharmacol Drug Dev 4*, 56-62. doi:10.1002/cpdd.133

Koytchev, R., Ozalp, Y., Erenmemisoglu, A. et al. (2004). Bioequivalence study of atorvastatin tablets. *Arzneimittelforschung 54*, 573-577. doi:10.1055/s-0031-1297051

Kropeit, D., von Richter, O., Stobernack, H. P. et al. (2018). Pharmacokinetics and safety of letermovir coadministered with cyclosporine a or tacrolimus in healthy subjects. *Clin Pharmacol Drug Dev 7*, 9-21. doi:10.1002/cpdd.388

Kumar, J. N., Devi, P., Narasu, L. et al. (2008). Effect of ciprofloxacin and ibuprofen on the in vitro metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers. *Eur J Drug Metab Pharmacokinet 33*, 237-242. doi:10.1007/BF03190878

Kumar, S. J., Prameela, D. and Mullangi, R. (2009). Effect of an antacid on the oral pharmacokinetics of rosiglitazone in healthy human volunteers. *INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH 43*, 162-165.

Kwon, K., Kim, M. H., Park, J. W. et al. (1995). Pharmacokinetics of two cyclosporine formulations using fpia and hplc assay in volunteers. *Archives of Pharmacal Research 18*, 385-390. doi:10.1007/bf02976340

Kyrklund, C., Backman, J. T., Kivisto, K. T. et al. (2001). Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. *Clin Pharmacol Ther 69*, 340-345. doi:10.1067/mcp.2001.115542

Lelawongs, P., Barone, J. A., Colaizzi, J. L. et al. (1988). Effect of food and gastric acidity on absorption of orally administered ketoconazole. *Clin Pharm 7*, 228-235.

Lilja, J., Kivisto, K. and Neuvonen, P. (1999). Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. *Clinical Pharmacology & Therapeutics 66*, 118-127. doi:10.1016/s0009-9236(99)90048-6

Liu, Y. M., Pu, H. H., Liu, G. Y. et al. (2010). Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted chinese adult males. *Clin Ther 32*, 1396-1407. doi:10.1016/j.clinthera.2010.07.004

Ma, L., Dong, J., Chen, X. J. et al. (2007). Development and validation of atorvastatin by lc–esi–ms and application in bioequivalence research in healthy chinese volunteers. *Chromatographia 65*, 737-741. doi:10.1365/s10337-007-0236-4

Mannisto, P. T., Mantyla, R., Nykanen, S. et al. (1982). Impairing effect of food on ketoconazole absorption. *Antimicrob Agents Chemother 21*, 730-733. doi:10.1128/AAC.21.5.730

Marcelin-Jimenez, G., Hernandez, J., Angeles, A. P. et al. (2004). Bioequivalence evaluation of two brands of ketoconazole tablets (onofin-k and nizoral) in a healthy female mexican population. *Biopharm Drug Dispos 25*, 203-209. doi:10.1002/bdd.399

Mazzu, A. L., Lasseter, K. C., Shamblen, E. C. et al. (2000). Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. *Clin Pharmacol Ther 68*, 391-400. doi:10.1067/mcp.2000.110537

McCrea, J. B., Menzel, K., Adedoyin, A. et al. (2022). Drug-drug interaction of letermovir and atorvastatin in healthy participants. *Clin Pharmacol Drug Dev 11*, 420-428. doi:10.1002/cpdd.1071

McKeand, W., Baird-Bellaire, S., Ermer, J. et al. (2018). A study of the potential interaction between bazedoxifene and atorvastatin in healthy postmenopausal women. *Clin Pharmacol Drug Dev 7*, 911-919. doi:10.1002/cpdd.458

Mendoza, L., Hajduch, M., Plausinaitis, R. et al. (2006). Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers. *Pharmazie 61*, 805-806.

Menon, R., Tolbert, D. and Cefali, E. (2007). The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet. *Biopharm Drug Dispos 28*, 297-306. doi:10.1002/bdd.555

Midha, K. K., Chakraborty, B. S., Schwede, R. et al. (1989). Comparative bioavailability of a new commercial tablet formulation and two lots of a reference formulation of haloperidol. *J Pharm Sci 78*, 443-447. doi:10.1002/jps.2600780603

Mignini, F., Tomassoni, D., Streccioni, V. et al. (2008). Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers. *Clin Exp Hypertens 30*, 95-108. doi:10.1080/10641960801944249

Miller, A. K., Inglis, A. M., Culkin, K. T. et al. (2001). The effect of acarbose on the pharmacokinetics of rosiglitazone. *Eur J Clin Pharmacol 57*, 105-109. doi:10.1007/s002280100275

Miller, A. K., DiCicco, R. A. and Freed, M. I. (2002). The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. *Clin Ther 24*, 1062-1071. doi:10.1016/s0149-2918(02)80019-4

Moraes, M. O., Lerner, F. E., Corso, G. et al. (1999). Fluoxetine bioequivalence study: Quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. *J Clin Pharmacol 39*, 1053-1061. doi:10.1177/00912709922011827

Mueller, E. A., Kovarik, J. M., Koelle, E. U. et al. (1993). Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration. *J Clin Pharmacol 33*, 936-943. doi:10.1002/j.1552-4604.1993.tb01926.x

Naik, H., Wu, J. T., Palmer, R. et al. (2012). The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a cyp2c8 substrate. *Br J Clin Pharmacol 74*, 327-335. doi:10.1111/j.1365-2125.2012.04182.x

Najib, N. M., Idkaidek, N., Beshtawi, M. et al. (2005). Bioequivalence evaluation of two brands of fluoxetine 20 mg capsules (flutin and prozac) in healthy human volunteers. *Biopharm Drug Dispos 26*, 243-247. doi:10.1002/bdd.456

Niemi, M., Backman, J. T., Granfors, M. et al. (2003). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. *Diabetologia 46*, 1319-1323. doi:10.1007/s00125-003-1181-x

Niemi, M., Backman, J. T. and Neuvonen, P. J. (2004). Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome p450 2c8 substrate rosiglitazone. *Clin Pharmacol Ther 76*, 239-249. doi:10.1016/j.clpt.2004.05.001

Ouellet, D., Hsu, A., Qian, J. et al. (1998). Effect of fluoxetine on pharmacokinetics of ritonavir. *Antimicrob Agents Chemother 42*, 3107-3112. doi:10.1128/AAC.42.12.3107

Palma-Aguirre, J. A., Gonzalez-Llaven, J., Flores-Murrieta, F. J. et al. (1997). Bioavailability of oral cyclosporine in healthy mexican volunteers: Evidence for interethnic variability. *J Clin Pharmacol 37*, 630-634. doi:10.1002/j.1552-4604.1997.tb04346.x

Paramanindita, A. S., Harahap, Y., Wijayanti, T. R. et al. (2021). Efficacy of deferasirox through bioequivalence study in indonesian healthy volunteer. *Iranian Journal of Blood and Cancer 13*, 48-53.

Patino-Rodriguez, O., Martinez-Medina, R. M., Torres-Roque, I. et al. (2015). Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: A randomized, crossover, study of a fixed-dose formulation in healthy mexican subjects. *Front Pharmacol 6*, 4. doi:10.3389/fphar.2015.00004

Pham, P. A., la Porte, C. J., Lee, L. S. et al. (2009). Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. *Antimicrob Agents Chemother 53*, 4385-4392. doi:10.1128/AAC.00449-09

Radwanski, E., Perentesis, G., Symchowicz, S. et al. (1989). Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. *J Clin Pharmacol 29*, 554-558. doi:10.1002/j.1552-4604.1989.tb03381.x

Rao, M. N., Mullangi, R., Katneni, K. et al. (2002). Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. *J Clin Pharmacol 42*, 670-675. doi:10.1177/00970002042006010

Saha, S. K., Chowdhury, A. A. and Bachar, S. C. (2014). Pharmacokinetics study of pioglitazone (30 mg) tablets in healthy volunteers. *Dhaka University Journal of Pharmaceutical Sciences 13*, 181-186.

Schafer-Korting, M., Korting, H. C., Dorn, M. et al. (1984). Ketoconazole concentrations in human skin blister fluid and plasma. *Int J Clin Pharmacol Ther Toxicol 22*, 371-374.

Schwartz, J. I., Stroh, M., Gao, B. et al. (2009). Effects of laropiprant, a selective prostaglandin d(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone. *Cardiovasc Ther 27*, 239-245. doi:10.1111/j.1755-5922.2009.00104.x

Sechaud, R., Dutreix, C., Balez, S. et al. (2008). Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. *Int J Clin Pharmacol Ther 46*, 102-108. doi:10.5414/cpp46102

Sechaud, R., Dumortier, T. and Balez, S. (2009). Deferasirox does not induce qt/qtc-prolongation in healthy subjects. *Int J Clin Pharmacol Ther 47*, 321-327. doi:10.5414/cpp47321

Shaefer, M. S., Rossi, S. J., McGuire, T. R. et al. (1995). Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. *Ann Pharmacother 29*, 1088-1091. doi:10.1177/106002809502901102

Shi, S., Liu, Y., Wu, J. et al. (2010). Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy chinese male volunteers: An open-label, randomized-sequence, two-period crossover study. *Clin Ther 32*, 1977-1986. doi:10.1016/j.clinthera.2010.10.003

Skerjanec, A., Wang, J., Maren, K. et al. (2010). Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. *J Clin Pharmacol 50*, 205-213. doi:10.1177/0091270009340418

Sohail, M., Ahmad, M. and Minhas, M. U. (2016). Single dose pharmacokinetics of atorvastatin oral formulations using a simple hplc-uv method. *Pak J Pharm Sci 29*, 1151-1154.

Solomon, W. D. S., Selvan, P. S., Gowda, K. Y. et al. (2007). Evaluation of bioequivalence of two formulations containing 200 mg of ketoconazole. *Asian Journal of Chemistry 19*, 5365-5371.

Sripalakit, P., Maphanta, S., Neamhom, P. et al. (2007). Comparative study on the bioequivalence of two formulations of pioglitazone tablet in healthy thai male volunteers. *Drug Dev Ind Pharm 33*, 1362-1368. doi:10.1080/03639040701484155

Teng, R., Mitchell, P. D. and Butler, K. A. (2013). Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. *Eur J Clin Pharmacol 69*, 477-487. doi:10.1007/s00228-012-1369-4

Tornio, A., Vakkilainen, J., Neuvonen, M. et al. (2015). Slco1b1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. *Pharmacogenet Genomics 25*, 382-387. doi:10.1097/FPC.0000000000000148

Vaidyanathan, S., Maboudian, M., Warren, V. et al. (2008). A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. *Curr Med Res Opin 24*, 2313-2326. doi:10.1185/03007990802259354

Van Den Abeele, J., Kostantini, C., Barker, R. et al. (2020). The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: An in vivo - in vitro investigation. *Eur J Pharm Sci 151*, 105377. doi:10.1016/j.ejps.2020.105377

Vella, S. and Floridia, M. (1998). Saquinavir. Clinical pharmacology and efficacy. *Clin Pharmacokinet 34*, 189-201. doi:10.2165/00003088-199834030-00002

Wittayalertpanya, S., Chompootaweep, S., Thaworn, N. et al. (2010). Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in thai healthy volunteers. *Journal of the Medical Association of Thailand 93*, 722-728.

Wring, S., Murphy, G., Atiee, G. et al. (2018). Lack of impact by scy-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for cyp450 2c8, supports the low risk for clinically relevant metabolic drug-drug interactions. *J Clin Pharmacol 58*, 1305-1313. doi:10.1002/jcph.1146

Young, D., Midha, K. K., Fossler, M. J. et al. (1993). Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: Implications for the involvement of cytochrome p450iid6. *Eur J Clin Pharmacol 44*, 433-438. doi:10.1007/BF00315539

Young, M. A., Lettis, S. and Eastmond, R. (1998a). Coadministration of acetaminophen and troglitazone: Pharmacokinetics and safety. *J Clin Pharmacol 38*, 819-824.

Young, M. A., Lettis, S. and Eastmond, R. (1998b). Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food. *Br J Clin Pharmacol 45*, 31-35. doi:10.1046/j.1365-2125.1998.00653.x

Young, M. A., Lettis, S. and Eastmond, R. (1998c). Concomitant administration of cholestyramine influences the absorption of troglitazone. *Br J Clin Pharmacol 45*, 37-40. doi:10.1046/j.1365-2125.1998.00645.x

Yuen, K. H., Wong, J. W., Billa, N. et al. (1999). Comparative bioavailability study of two ketoconazole tablet preparations. *Med J Malaysia 54*, 482-486.

Yun, J. Y., Kim, B.-H., Lee, J. H. et al. (2016). Screening study for genetic polymorphisms affecting pharmacokinetics of pioglitazone. *Translational and Clinical Pharmacology 24*, 194-202.

Yun, M. H., Kwon, J. T. and Kwon, K. I. (2005). Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. *Arch Pharm Res 28*, 488-492. doi:10.1007/BF02977681

Yusuf, A., Al-Gaai, E. and Hammami, M. M. (2006). Bioequivalence evaluation of two rosiglitazone tablet formulations. *Arzneimittelforschung 56*, 740-743. doi:10.1055/s-0031-1296784

Zhou, L. X., Finley, D. K., Hassell, A. E. et al. (1995). Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers. *Journal of Pharmacology and Experimental Therapeutics 273*, 121-127.